Curia 投资 400 万美元改进无菌原料药（API）的制造

Core Insights - Curia Global, Inc. has completed a $4 million investment to upgrade two sterile Active Pharmaceutical Ingredient (API) production lines in Valladolid, Spain, aligning with the latest EU GMP standards [1][2] - The investment focuses on modernizing infrastructure and technology, including the installation of new isolation devices and upgrades to HVAC, automation, and sterilization systems, aiming for a fully enclosed system to enhance product safety and prevent contamination [2][3] - Curia's commitment to quality and compliance is emphasized by CEO Philip Macnabb, highlighting the importance of reliability and precision in meeting customer needs [2][3] Investment Details - The investment primarily funds facility equipment updates and aims to support increasingly complex manufacturing projects [2][3] - Ergonomic improvements for operators and enhanced automation controls are key measures to ensure operational safety and compliance with stricter data integrity policies [2] Company Background - Curia is a contract research, development, and manufacturing organization (CDMO) with over 30 years of experience, operating a network of 20 global facilities and employing 3,200 staff [4] - The company provides comprehensive services from discovery to commercialization in small molecule drugs, generic APIs, sterile formulations, and biologics, focusing on regulatory integration and analytical testing [4]